TELZUIT MEDICAL TECHNOLOGIES, INC.
Form: 10KSB Filing Date: 10/13/2006
Manufacturing Capacity
We have begun the production of our STATPATCH tm utilizing third party FDA-certified contract manufacturers. Most of the components of our products are standard parts available from multiple supply sources at competitive prices. This, coupled with the significant start-up cost advantages associated with contractors, minimizes production and product costs.
Sales and Marketing
We intend to market our products and services directly to physicians and other medical care providers, and plan to also use strategic alliances with independent medical distributors. Once our heart monitoring device is ready to market, we plan to assemble an in-house sales force to promote and offer our products. We believe that a direct sales approach will enable us to maintain control over our relationship with the medical community and allow for better product feedback to take place.
Our sales staff intends to promote our products and services at regional and national conventions, medical trade shows and through professional organizations. We also intend to utilize more conventional means to market and promote our products and services, such as advertisements through medical publications, press releases, direct mail, internet web sites and product samples.
Pricing Strategy
Our revenues are anticipated to come primarily through reimbursements from Medicare and insurance providers for the monitoring and information collecting services that we will provide. Current Medicare and most insurance coverage provides reimbursements for heart monitoring and analysis, heart activity recording and patient activation services. We may also sell the STATPATCH TM System to medical practices and payors of medical care.
Physicians who prescribe heart-monitoring devices also receive reimbursements from Medicare and insurance providers for patient hook-up, patient evaluation, and data review services they provide.
News 
Market Data 
Discover 
